Edition:
India

Entera Bio Ltd (ENTX.OQ)

ENTX.OQ on NASDAQ Stock Exchange Capital Market

1.29USD
9:43pm IST
Change (% chg)

$-0.03 (-2.27%)
Prev Close
$1.32
Open
$1.34
Day's High
$1.34
Day's Low
$1.26
Volume
7,419
Avg. Vol
99,319
52-wk High
$3.35
52-wk Low
$1.00

Latest Key Developments (Source: Significant Developments)

Entera Bio Announces Interim Data From Phase 2 Clinical Trial Of Eb613 In Osteoporosis
Thursday, 20 Aug 2020 

Aug 20 (Reuters) - Entera Bio Ltd ::ENTERA BIO LTD ANNOUNCES INTERIM DATA FROM PHASE 2 CLINICAL TRIAL OF EB613 IN OSTEOPOROSIS AND SECOND QUARTER 2020 FINANCIAL RESULTS.ENTERA BIO - 6-MONTH INTERIM DATA INDICATE EB 613 HAS MEANINGFUL AND POSITIVE IMPACT ON LUMBAR SPINE BONE MINERAL DENSITY IN DOSE DEPENDENT MANNER.ENTERA BIO LTD - BASED ON 6-MONTH DATA, EB613 GENERATED A MEAN PLACEBO ADJUSTED INCREASE IN LUMBAR SPINE BMD OF 2.15%.  Full Article

Entera Bio Files For Shelf Of Upto 9.6 Mln Shares By Selling Stockholders
Saturday, 6 Jun 2020 

June 5 (Reuters) - Entera Bio Ltd ::ENTERA BIO FILES FOR SHELF OF UPTO 9.6 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Entera Bio Reports Q1 Loss Per Share Of $0.16
Thursday, 21 May 2020 

May 21 (Reuters) - Entera Bio Ltd ::ANNOUNCES INTERIM BIOMARKER DATA FROM PHASE 2 CLINICAL TRIAL OF EB613 AND FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.16.STATISTICALLY SIGNIFICANT ONE MONTH INCREASES IN P1NP BIOMARKER FROM FIRST 50% OF PATIENTS WITH HIGHEST DOSE OF EB613.CO TO FOLLOW PATIENTS IN PHASE 2 CLINICAL TRIAL OF EB613 THROUGH 6 MONTHS FOR BONE MINERAL DENSITY DATA.INTENDS TO EVALUATE ADDITIONAL DOSES GREATER THAN 1.5MG TO ADVANCE INTO A POTENTIAL PHASE 3 STUDY, IF APPROPRIATE.CO TO EVALUATE ADDITIONAL HIGHER DOSES OF EB613.EXPECTS AN OPERATING LOSS OF APPROXIMATELY $10 MILLION FOR YEAR ENDING DECEMBER 31, 2020.BELIEVES ITS CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q2 OF 2021..TARGETING COMPLETION OF ENROLLMENT FOR EB613 IN Q3 OF 2020, SUBJECT TO ANY COVID IMPACTS.BELIEVES ITS CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q2 OF 2021.  Full Article

Entera Bio Announces Financial And Operating Results For The Fourth Quarter And Year Ended December 31, 2019
Thursday, 26 Mar 2020 

March 26 (Reuters) - Entera Bio Ltd ::ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019.ENTERA BIO LTD - EXPECTS AN OPERATING LOSS OF BETWEEN $10 MILLION AND $12 MILLION FOR THE YEAR ENDING DEC 31, 2020.ENTERA BIO LTD - CORPORATE OBJECTIVES FOR 2020 MAY BE MATERIALLY AND NEGATIVELY IMPACTED BY THE COVID-19.ENTERA BIO- 3 MONTH BIOMARKER DATA FROM PHASE 2 CLINICAL TRIAL OF EB613 EXPECTED IN Q2 OF 2020 WITH ADDITIONAL DATA READOUTS EXPECTED IN 2020 & EARLY 2021.  Full Article

Entera Bio Posts Third-Quarter Loss Per Share Of 25 Cents
Thursday, 21 Nov 2019 

Nov 21 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATING UPDATE.ENTERA BIO LTD - ENROLLMENT CONTINUES FOR PHASE 2 STUDY FOR ORAL PTH IN OSTEOPOROSIS; TOP-LINE 3-MONTH BIOMARKER DATA EXPECTED IN MID 2020.ENTERA BIO LTD - QTRLY LOSS PER SHARE $0.25.ENTERA BIO LTD - EXPECTS TOP-LINE DATA FOR PHASE 2 STUDY FOR ORAL PTH IN OSTEOPOROSIS FROM FULL 3-MONTH BIOMARKER ENDPOINT IN Q3 OF 2020.ENTERA BIO LTD - EXPECTS TOP-LINE DATA FOR PHASE 2 STUDY FOR ORAL PTH IN OSTEOPOROSIS FROM INTERIM (50%) 3-MONTH BIOMARKER ENDPOINT IN Q2 OF 2020.  Full Article

Entera Bio Q2 Loss Per Share $0.12
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES OPERATING UPDATE.Q2 LOSS PER SHARE $0.12.QTRLY CASH AND CASH EQUIVALENTS $7.4 MILLION AS OF JUNE 30.  Full Article

Entera Bio Appoints Adam Gridley As CEO
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Entera Bio Ltd ::ENTERA BIO APPOINTS ADAM GRIDLEY AS CHIEF EXECUTIVE OFFICER.ENTERA BIO LTD - PHILLIP SCHWARTZ WILL CONTINUE WITH COMPANY AS PRESIDENT OF RESEARCH & DEVELOPMENT AND EXECUTIVE VICE PRESIDENT AT ENTERA.ENTERA BIO LTD - GRIDLEY WAS PRESIDENT AND CEO, AND A DIRECTOR OF HISTOGENICS CORP.  Full Article

Entera Bio Reports Q1 Loss Per Share $0.26
Thursday, 27 Jun 2019 

June 27 (Reuters) - Entera Bio Ltd ::ENTERA BIO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND OPERATING UPDATE.Q1 LOSS PER SHARE $0.26.CASH, CASH EQUIVALENTS AND SHORT-TERM DEPOSITS AT MARCH 31, 2019 WERE $9.6 MILLION.COMPLETED PART 2 OF A PHASE 2 PK/PD STUDY IN HYPOPARATHYROIDISM PATIENTS..  Full Article

Check-Cap Appoints Mira Rosenzweig As CFO
Monday, 18 Mar 2019 

March 18 (Reuters) - Check Cap Ltd ::CHECK-CAP ANNOUNCES APPOINTMENT OF MIRA ROSENZWEIG AS CHIEF FINANCIAL OFFICER.CHECK CAP LTD - ROSENZWEIG MOST RECENTLY SERVED AS CFO OF ENTERA BIO LTD.  Full Article

Entera Bio Announces Positive Feedback, Guidance From US FDA Regarding Its Development Plans For Oral PTH In Osteoporosis
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Entera Bio Ltd ::ENTERA BIO ANNOUNCES POSITIVE FEEDBACK AND GUIDANCE FROM THE US FDA REGARDING ITS DEVELOPMENT PLANS FOR ORAL PTH IN OSTEOPOROSIS.ENTERA BIO - BELIEVES THAT PHASE 3 STUDY MAY USE BMD AS PRIMARY EFFICACY ENDPOINT AND THAT A FRACTURE ENDPOINT STUDY WILL NOT BE REQUIRED.ENTERA BIO LTD - POST FDA FEEDBACK, COMPANY IS PROCEEDING WITH DEVELOPMENT OF EB-613 FOR OSTEOPOROSIS.  Full Article

BRIEF-Entera Bio Ltd Provides Update On Phase 2 Clinical Trial Of Eb613 In Postmenopausal Women With Osteoporosis

* ENTERA BIO LTD PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF EB613 IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS